Novo Nordisk believes that good public policy can move the U.S. forward in lessening the burden and impact of diabetes in America. We use the Barometer’s Measure, Share, Improve framework to guide how we approach policymakers about issues and opportunities for improving quality of care and outcomes for people living with diabetes and prediabetes.
Novo Nordisk is a founding member of the Diabetes Advocacy Alliance™ (DAA), and a co-chair along with the Academy of Nutrition and Dietetics (AND) and the Pediatric Endocrine Society (PES). The DAA is a coalition with 20 members that represent patient, professional and trade associations, other nonprofit organizations, and corporations, united in the desire to change the way diabetes is viewed and treated in America.
Learn more about the initiatives and activities of the Diabetes Advocacy Alliance.
© 2016 Novo Nordisk All rights reserved. 0415-00026489-1 January 2016